“We leverage our drug development and regulatory strategies in order to optimize the success rate of the clinical development path and we are keenly interested in blockbuster-drugs, orphan drug indications and serious and debilitating indications, as well as innovative and cutting-edge treatment molecules. By combining our drug development expertise on these initial and positive pioneering studies with SELLAS’ strength in delivering breakthrough therapeutics to improve people’s lives, we have the potential to transform a therapeutic paradigm-shift of Cancer and CNS treatments..."
Dr. Angelos M. Stergiou, CEO & Chairman, SELLAS LIFE SCIENCES GROUP.
We strive to achieve excellence in developing treatments in the areas of CNS diseases and cancer through:
Partnering with renowened Hospitals, Clinical Development and Pharmaceutical companies
Developing drugs into Phase I/II & III clinical development paths and seeks out-licensing opportunities and deals
Finding approved drugs developed for new indications that are patent protected